Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2007

01-04-2007 | ORIGINAL ARTICLE

Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer

Authors: Kotaro Miyake, Satoru Imura, Tomoharu Yoshizumi, Tetsuya Ikemoto, Yuji Morine, Mitsuo Shimada

Published in: International Journal of Clinical Oncology | Issue 2/2007

Login to get access
Metadata
Title
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer
Authors
Kotaro Miyake
Satoru Imura
Tomoharu Yoshizumi
Tetsuya Ikemoto
Yuji Morine
Mitsuo Shimada
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 2/2007
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-006-0634-x

Other articles of this Issue 2/2007

International Journal of Clinical Oncology 2/2007 Go to the issue

CASE REPORT

Paraneoplastic vasculitis of central nervous system presenting as recurrent cryptogenic stroke

CASE REPORT

Malignant paraganglioma arising from the kidney

CASE REPORT

Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy

ORIGINAL ARTICLE

Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1

REVIEW ARTICLE

CT-guided radiofrequency ablation for lung cancer

ORIGINAL ARTICLE

Lymphatic invasion is a prognostic factor for bladder cancer treated with radical cystectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits